JAMES B. BREITMEYER - 03 Jan 2024 Form 4 Insider Report for Oncternal Therapeutics, Inc.

Role
Chief Executive Officer, Director
Signature
/s/Chase C. Leavitt, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
03 Jan 2024
Net transactions value
-$27,504
Form type
4
Filing time
05 Jan 2024, 16:00:17 UTC
Previous filing
04 Oct 2023
Next filing
15 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ONCT Common Stock Tax liability $25,279 -50,955 -10% $0.4961 443,034 03 Jan 2024 Direct F1
transaction ONCT Common Stock Tax liability $2,225 -4,485 -23% $0.4961 15,426 03 Jan 2024 By Spouse F1
holding ONCT Common Stock 196,544 03 Jan 2024 By Family Trust
holding ONCT Common Stock 733 03 Jan 2024 By Child
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by the Issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units.